


VIEW IN FRAME

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

aidsline
NATIONAL LIBRARY OF MEDICINE



Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1.

J Infect Dis. 1996 Jul;174(1):63-8. Unique Identifier : AIDSLINE MED/96261994

Walker RE; Spooner KM; Kelly G; McCloskey RV; Woody JN; Falloon J; Baseler M; Piscitelli SC; Davey RT Jr; Polis MA; Kovacs JA; Masur H; Lane HC; National Institute of Allergy and Infectious Diseases, Critical Care Medicine Department, National Institutes of Health,; Bethesda, MD 20892, USA.

Abstract: Tumor necrosis factor-alpha (TNF-alpha), a proinflammatory cytokine known to stimulate human immunodeficiency virus type 1 (HIV-1) replication, has been implicated in the pathogenesis of HIV-1 infection. Inhibition of TNF-alpha by a chimeric humanized monoclonal antibody, cA2, was investigated in 6 HIV-1-infected patients with CD4 cell counts < 200/mm³. Two consecutive infusions of 10 mg/kg 14 days apart were well tolerated, and a prolonged serum half-life for cA2 (mean, 257 +/- 70 h) was demonstrated. Serum immunoreactive TNF-alpha concentrations fell from a mean prestudy value of 6.4 pg/mL (range, 4.2-7.9) to 1.1 pg/mL (range, 0.5-2.2) 24 h after the first infusion and returned to baseline within 7-14 days. A similar response was seen after the second infusion. No consistent changes in CD4 cell counts or plasma HIV RNA levels were observed over 42 days. Future studies evaluating the therapeutic utility of long-term TNF-alpha suppression using anti-TNF-alpha antibodies are feasible and warranted.

Keywords: Acquired Immunodeficiency Syndrome/BLOOD/*IMMUNOLOGY Adult Animal Antibodies/*THERAPEUTIC USE Antibodies, Monoclonal/*THERAPEUTIC USE Chimeric Proteins/PHARMACOKINETICS/*THERAPEUTIC USE Female Human *HIV-1 Male Mice Recombinant Proteins/PHARMACOKINETICS/THERAPEUTIC USE Tumor Necrosis Factor/*ANTAGONISTS & INHIB/IMMUNOLOGY JOURNAL ARTICLE

961030

M96A1322

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGIS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGIS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGIS. All materials appearing on AEGIS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGIS, or the party credited as the provider of the content. comments@aegis.org.

